Praziquantel, Pyrantel Pamoate & Febantel

Verify with FDA CVM →

76 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
76
Total Reports
3
Deaths Reported
390.0%
Death Rate

Active Ingredients

Praziquantel, Pyrantel Pamoate & Febantel

Administration Routes

OralUnknown

Species Affected

Dog 68
Cat 8

Most Affected Breeds

Greyhound 10
Shepherd Dog - German 7
Retriever - Labrador 7
Crossbred Canine/dog 5
Domestic Shorthair 5
Shih Tzu 4
Terrier - Yorkshire 3
Terrier - Bull - American Pit 3
Shepherd Dog - Australian 3
Chihuahua 2

Most Reported Reactions

Vomiting 16
Lack of efficacy (endoparasite) - NOS 15
Lethargy (see also Central nervous system depression in 'Neurological') 12
Ataxia 8
Anorexia 6
Diarrhoea 6
Decreased appetite 5
Fever 5
Lack of efficacy (endoparasite) - hookworm 5
Seizure NOS 4
Behavioural disorder NOS 4
Nystagmus 4

Outcome Breakdown

Ongoing
52 (68.4%)
Recovered/Normal
18 (23.7%)
Outcome Unknown
3 (3.9%)
Died
2 (2.6%)
Euthanized
1 (1.3%)

Data Summary

Metric Value
Total adverse event reports 76
Reports involving death 3
Case-fatality rate (reported events) 390.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Praziquantel, Pyrantel Pamoate & Febantel Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 76 adverse event reports referencing Praziquantel, Pyrantel Pamoate & Febantel, including 3 reports in which the animal died — a 390.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Praziquantel, Pyrantel Pamoate & Febantel. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Praziquantel, Pyrantel Pamoate & Febantel reports are Dog (68 reports), Cat (8 reports), with Dog accounting for the largest share. Within those species, Greyhound (10), Shepherd Dog - German (7), Retriever - Labrador (7) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Praziquantel, Pyrantel Pamoate & Febantel are Vomiting (16), Lack of efficacy (endoparasite) - NOS (15), Lethargy (see also Central nervous system depression in 'Neurological') (12), Ataxia (8). Of the 76 reports with a coded outcome, Ongoing is the leading category at 68.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Praziquantel, Pyrantel Pamoate & Febantel.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial